A consistent focus on customers and their challenges
Tiffani Manolis, Director, Global Pharma Segment Marketing, Agilent Technologies, explains how her company’s solutions and portfolio have evolved with the pharma industry.
List view / Grid view
Articles
Biopharmaceutical Development & Processing
This In-Depth Focus looks at QbD and PAT for cutting biopharma attrition rates as well as continuous freeze-drying technology for biopharma products...
Looking back, looking forward
The pharmaceutical industry has seen a lot of change in the last 21 years. In 1996 the internet was relatively new and limited to computer access, mobile devices were bulky and expensive, and security concerns were primarily physical. Similarly, a lot has changed with regards to business, manufacturing and regulation,…
Driving growth in emerging markets
Mark Quick, Executive Vice-president, Corporate Development at Recipharm, explains how his company has set about becoming a best-in-class provider of contract development and manufacturing solutions to the pharmaceutical industry.
Strong partnership environment heralds success in pharma
Catalent believes it is essential to share knowledge and experience to improve understanding of drug formulation and delivery challenges and contribute jointly to finding solutions. Will Downie, Senior Vice President, Global Sales and Marketing at Catalent, explains how his company makes a success of this strategy...
Continuous evolution and reinvention in biopharma
Andreas Weiler, Business Unit Head for Emerging Technologies, and Fatma Senkesen, Marketing Intelligence Associate Director, at Lonza, explain how their company has kept in step with industry developments.
A complete set of capabilities across the entire drug continuum
Since 2014, AMRI has significantly expanded its service and product range through several acquisitions. Today, it has more than 3,100 employees at 27 locations in the US, UK, Europe and Asia, and it continues to seek new opportunities in areas of complex science. William S Marth, President and Chief Executive…
How pharma operations in Europe have changed in the last 25 years
Twenty five years ago, the European Community took a major step toward political and economic union by adopting the Treaty of Maastricht. The Treaty created the European Union (EU), paving the way for closer economic ties within the Union through the free movement of goods between member states. This opening…
Personalised medicine and partnering – key areas for Ferring
Michel Pettigrew, President of the Executive Board and Chief Operating Officer at Ferring Pharmaceuticals, explains how his company’s decentralised model and focus on entrepreneurialism is helping it to deliver personalised medicine.
Kyowa Kirin: Creating opportunities from challenges
Dr Masashi Miyamoto, Director of the Board, Managing Executive Officer, Director of Corporate Strategy & Planning Department at Kyowa Hakko Kirin, explains his company’s five-year mid-term plan (2016-2020) to become a global specialty pharmaceutical company, and other significant initiatives...
How Mylan is meeting challenges in sustainability
Mylan works with industry associations and key stakeholders to improve sustainability of the healthcare system. Jacek Glinka, President, Mylan Europe, explains how...
Boehringer Ingelheim: Achievements to be proud of
Allan Hillgrove, Member of the Board of Managing Directors with responsibility for the Human Pharma Business Unit at Boehringer Ingelheim, tells EPR about some of his company’s achievements that he is most proud of, and describes how it will face the digital challenge...
Allergan: Living bold and doing what’s right
Marc Princen, Executive Vice President and President Allergan International, explains how Allergan’s novel ethos and innovative approach makes it stand out from the crowd...
Rational drug design: How far have we come?
From the early use of Hansch parameters and Topliss Trees to today’s computational structure–activity techniques, medicinal chemists have long sought to rationalise drug design to find the quickest and most resource-efficient route to market. But while modern strategies are more reliant on statistical algorithms and vast data libraries, these founding…
What’s next for big data?
The emergence of big data, technological innovations and advancements in scientific research is set to be transformative for the pharmaceutical industry, providing faster access to insights that can drive more informed decision making and accelerate drug development. Dr Chris Barber, CEO of Lhasa Limited, looks at what is next for…
